top of page
Latest News

News: Latest News

Code Biotherapeutics Appoints Erin Brubaker as Chief Operating Officer

- Biopharma executive with nearly 30 years of experience will help deliver on company’s mission of transforming care for rare and genetic diseases through the use of its novel 3DNA® delivery platform

Hatfield, PA — December 2, 2021 — Code Biotherapeutics, Inc., a biotechnology company pioneering targeted non-viral delivery of genetic medicines, announces the appointment of Erin Brubaker as Chief Operating Officer, effective immediately.


“I am thrilled to welcome Erin to our Executive team,” said Code Bio Chairman, Chief Executive Officer, and Co-Founder Brian P. McVeigh. “Erin’s exceptional leadership skills, extensive experience developing strategy and driving operational excellence across corporate, R&D, and commercial organizations, expertise in integrating science and customer insights into commercial strategies that result in successful product launches, and her proven track record of developing high-performing teams will all serve Code Bio well as we continue to grow and advance our pipeline of important new genetic medicines for patients in need.”


In her role as COO, Ms. Brubaker is leading corporate strategy and focusing on the buildout of the broader organization, with oversight of finance, manufacturing, human resources, information technology, legal, compliance, real estate and facilities, program and project management, corporate communications, and early commercial strategy.


Ms. Brubaker brings to this role extensive experience in the pharmaceutical and biotechnology industry including more than 20 years with GlaxoSmithKline Pharmaceuticals where she held positions of increasing responsibility enterprise-wide across R&D and commercial businesses. Most recently she served as Vice President Corporate Development at Passage Bio, a fully integrated gene therapy company.


“Code Bio has a unique opportunity to deliver targeted, non-viral gene therapies with its proprietary 3DNA delivery platform,” said Ms. Brubaker. “It’s a privilege to join the team and build the infrastructure that will enable delivery of the early pipeline in Duchenne Muscular Dystrophy and Type 1 Diabetes as well as enable future pipeline expansion into other rare and prevalent genetic diseases.”


Ms. Brubaker holds a Bachelor of Arts from Franklin & Marshall College. She also completed the Transformational Leadership for Executives program through Wharton Business School at the University of Pennsylvania and holds  professional certifications in Executive Coaching and Alliance Management. Ms. Brubaker is currently an Executive Board member for Life Sciences Pennsylvania.

About Code Bio therapeutics, Inc.

Headquartered in Greater Philadelphia, Code Bio is a next-generation genetic medicines company pioneering the development of targeted non-viral gene therapies to treat and potentially cure serious and life-threatening genetic diseases.  Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The Company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases. For more information, visit


Media Contact:

Mike Beyer
Sam Brown Inc. Healthcare Communications


bottom of page